Zotepine.txt CLINICAL USE Treatment of schizophrenia DOSE IN NORMAL RENAL FUNCTION 25–100 mg 3 times a day PHARMACOKINETICS Molecular weight                           : 331.9 %Protein binding                           : 97 %Excreted unchanged in urine     : <0.1 (40% as metabolites) Volume of distribution (L/kg)       : 50–168 half-life – normal/ESRD (hrs)      : 14/Increased DOSE IN RENAL IMPAIRMENT GFR (mL/MIN) 20 to 50     : 25 mg twice daily increasing to 75 mg twice daily 10 to 20     : 25 mg twice daily increasing to 75 mg twice daily <10           : 25 mg twice daily increasing to 75 mg twice daily DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES CAPD                : Unknown dialysability. Dose as GFR <10 mL/min HD                     : Unknown dialysability. Dose as GFR <10 mL/min HDF/high flux   : Unknown dialysability. Dose as GFR <10 mL/min CAV/VVHD      : Unknown dialysability. Dose as GFR 10 to 20 mL/min IMPORTANT DRUG INTERACTIONS Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect Analgesics: increased risk of convulsions with tramadol; enhanced hypotensive and sedative effects with opioids Antidepressants: concentration increased by fluoxetine; concentration of tricyclics possibly increased Anti-epileptics: antagonism, as convulsive threshold lowered Antimalarials: avoid concomitant use with artemether/lumefantrine Antivirals: concentration possibly increased by ritonavir Anxiolytics and hypnotics: enhanced sedative effects; concentration increased by diazepam Sibutramine: increased risk of CNS toxicity – avoid concomitant use ADMINISTRATION Reconstition – Route Oral Rate of Administration – Comments – OTHER INFORMATION Do not use if there is a history of nephrolithiasis Occasionally can increase creatinine levels Undergoes extensive first pass metabolism . Tags: post-by-auto-php Continue Reading Previous Previous post: VOLVULUS.txtNext Next post: Zuclopenthixol.txt Related News sotalol hydrochloride.txt tazocin.txt